Erratum to: Hepatol Int DOI 10.1007/s12072-007-9009-2
In the online and print edition of this article, the following statement appears incorrectly in the discussion section:
In HBeAg-positive patients, entecavir showed superiority over lamivudine for HBV DNA <300 (90% vs. 72%) and ALT normalization (78% vs. 71%).
The correct statement is as follows:
In HBeAg-negative patients, entecavir showed superiority over lamivudine for HBV DNA <300 (90% vs. 72%) and ALT normalization (78% vs. 71%).
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The online version of the original article can be found under doi: 10.1007/s12072-007-9009-2.
Rights and permissions
About this article
Cite this article
Yao, G., Chen, C., Lu, W. et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2, 136 (2008). https://doi.org/10.1007/s12072-007-9043-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-007-9043-0